Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generation antibody-drug conjugates (ADCs) and multispecific antibodies. Under the agreement, Innovent will lead early clinical development through Phase I, while Pfizer will take over global development and commercialization.
The collaboration highlights how Pfizer is increasingly moving beyond traditional in-house R&D and turning toward biotechnology compan...
